NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Clinical trials for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED trials appear
Sign up with your email to follow new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Dual-Targeting CAR t therapy aims to outperform standard treatment for blood cancer
Disease control Recruiting nowThis Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 04:00 UTC
-
New immune cell therapy takes on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called CD19 t-haNK, which uses specially engineered immune cells to target and kill lymphoma cells. It is for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The study will c…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma in new trial
Disease control Recruiting nowThis study tests a one-time treatment using the patient's own immune cells, modified to attack cancer cells, in adults with a type of blood cancer (non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The goal is to see how well the treatment shrinks tum…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE2 • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy offers hope for patients with resistant lymphomas
Disease control Recruiting nowThis study tests whether adding ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with certain lymphomas that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combination. The go…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE2 • Sponsor: Seda S. Tolu • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for hard-to-treat lymphoma? early trial of LTZ-301 begins
Disease control Recruiting nowThis early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC